title: Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).
abstract: 1. The study aimed to investigate the pharmacokinetics of cryptotanshinone in a hydroxylpropyl-beta-cyclodextrin-included complex in dogs and rats. 2. Animals were administrated the inclusion complex of cryptotanshinone and the concentrations of cryptotanshinone and its major metabolite tanshinone IIA were determined by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. 3. Cryptotanshinone in inclusion complex was absorbed slowly after an oral dose, and the C(max) and AUC(0-)(t) were dose-proportional. The bioavailability of cryptotanshinone in rats was (6.9% +/- 1.9%) at 60 mg kg(-1) and (11.1% +/- 1.8%) in dogs at 53.4 mg kg(-1). The t(1/2) of the compound in rats and dogs was 5.3-7.4 and 6.0-10.0 h, respectively. Cryptotanshinone showed a high accumulation in the intestine, lung and liver after oral administration, while the lung, liver and heart had the highest level following intravenous dose. Excretion data in rats showed that cryptotanshinone and its metabolites were mainly eliminated from faeces and bile, and the dose recovery rate was 0.02, 2.2, and 14.9% in urine, bile, and faeces, respectively. 4. The disposition of cryptotanshinone in an inclusion complex was dose-independent and the bioavailability was increased compared with that without cyclodextrin used to formulate the drug. Cryptotanshinone was distributed extensively into different organs. Excretion of cryptotanshinone and its metabolites into urine was extremely low, and they were mainly excreted into faeces and bile.
authors.affiliation: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Pan
authors.forename: H-C
authors.initials: HC
authors.lastname: Bi
authors.forename: G-P
authors.initials: GP
authors.lastname: Zhong
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: Z
authors.initials: Z
authors.lastname: Zuo
authors.forename: L-Z
authors.initials: LZ
authors.lastname: Zhao
authors.forename: L-Q
authors.initials: LQ
authors.lastname: Gu
authors.forename: P-Q
authors.initials: PQ
authors.lastname: Liu
authors.forename: Z-Y
authors.initials: ZY
authors.lastname: Huang
authors.forename: S-F
authors.initials: SF
authors.lastname: Zhou
authors.forename: M
authors.initials: M
authors.lastname: Huang
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D045784:Abietanes; D000284:Administration, Oral; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004285:Dogs; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D008297:Male; D010616:Phenanthrenes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010618:Phenanthrolines / Q000737:chemistry; D051381:Rats; D027561:Salvia miltiorrhiza / Q000737:chemistry; D014018:Tissue Distribution; D047392:beta-Cyclodextrins / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D045784:Abietanes; D002317:Cardiovascular Agents; D004365:Drugs, Chinese Herbal; D015507:Drugs, Investigational; D010616:Phenanthrenes; D010618:Phenanthrolines; D047392:beta-Cyclodextrins; C021751:tanshinone; C028972:dan-shen root extract; D000073738:2-Hydroxypropyl-beta-cyclodextrin; C037886:cryptotanshinone